Bal Pharma DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	1.06×	1.07×	1.40×	0.82×	0.55×
	0.31×	0.28×	0.26×	0.42×	0.30×
	6.7%	6.7%	6.5%	6.3%	5.3%
	0.88×	0.88×	0.92×	1.07×	0.97×
	4.57×	4.57×	4.34×	4.63×	4.92×
	8.7%	8.1%	9.5%	10.9%	4.1%
	7.9%	7.9%	9.8%	11.1%	4.1%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

BALPHARMA₹84.61

Bal Pharma Limited

· Pharma & Health

₹ CrorePeersALPA KREBSBIO NATCAPSUQ VINEETLAB NECLIFE AAREYDRUGS BIOFILCHEM MANGALAMMcap ₹135 Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.55	0.82	1.40	1.07	1.06
Interest Burden (Pretax/EBIT) ×	0.30	0.42	0.26	0.28	0.31
EBIT Margin %	5.26	6.33	6.53	6.68	6.71
Asset Turnover ×	0.97	1.07	0.92	0.88	0.88
Financial Leverage (Assets/Equity) ×	4.92	4.63	4.34	4.57	4.57
ROE (5-step product, year-end total equity) %	4.11	10.86	9.48	8.15	8.71
ROE (owners' profit / average owners' equity) %	4.11	11.11	9.84	7.87	7.87

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.